SCHEMBL2076366

SCHEMBL2076366

c1ccc2c(N3CCNCC3)nccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 1.00
HRH4 Q9H3N8 1/20 0.67
NCF1 P14598 2/20 0.56
HTR6 P50406 2/20 0.56
HTR3E A5X5Y0 1/20 0.56
HTR3B O95264 1/20 0.56
CYP1A2 P05177 1/20 0.56
HTR1A P08908 1/20 0.56
CYP2D6 P10635 1/20 0.56
TSHR P16473 1/20 0.56
NFKB1 P19838 1/20 0.56
HTR1D P28221 1/20 0.56
HTR1B P28222 1/20 0.56
HTR2A P28223 1/20 0.56
HTR7 P34969 1/20 0.56
MTOR P42345 1/20 0.56
HTR3A P46098 1/20 0.56
HTR5A P47898 1/20 0.56
HTR3D Q70Z44 1/20 0.56
HTR3C Q8WXA8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040877 1.00 HTR2C (1.00) HTR2CHRH4NCF1HTR6HTR3E
Hydrochloric Acid SCHEMBL1532881 0.98 HTR2C (0.97) HTR2CHRH4NCF1HTR6HTR3E
SCHEMBL27456544 0.94 HTR2C (0.88) HTR2CHRH4NCF1HTR6HTR3E
Fumaric Acid SCHEMBL10429817 0.88 HTR2C (0.77) HTR2CHRH4NCF1HTR6HTR3E
Fumaric Acid SCHEMBL10429816 0.88 HTR2C (0.77) HTR2CHRH4NCF1HTR6HTR3E
SCHEMBL30275021 0.84 HRH4 (0.73) HTR2CHRH4TSHRHSD17B10SORD
SCHEMBL29003692 0.84 HRH4 (0.73) HTR2CHRH4TSHRHSD17B10SORD
SCHEMBL4766806 0.83 HRH4 (0.71) HTR2CHRH4TSHRHSD17B10SORD
SCHEMBL3690677 0.82 HTR2C (0.69) HTR2CNCF1HTR6ADRB2
SCHEMBL2202162 0.81 HRH4 (0.69) HTR2CHRH4NCF1SORD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768826-A Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof 中国科学院新疆理化技术研究所 2023-09-19 CN claimed
US-7799775-B2 such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-09-21 US claimed
EP-0343050-B1 6-PHENYL-3-PIPERAZINYLALKYL 1H,3H-PYRIMIDINEDIONE-2,4 DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPY SYNTHELABO (FR) 1992-12-02 EP claimed
EP-0189612-B1 NEW PHARMACEUTICAL COMPOSITIONS HAVING A PSYCHOTROPIC ACTIVITY DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1992-11-04 EP claimed
EP-0189612-A1 New pharmaceutical compositions having a psychotropic activity DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1986-08-06 EP claimed
CN-116768826-A Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof 中国科学院新疆理化技术研究所 2023-09-19 CN disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 EP disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed
EP-3233827-B1 ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY ACRAF (IT) 2020-07-08 EP disclosed
EP-0189612-B1 NEW PHARMACEUTICAL COMPOSITIONS HAVING A PSYCHOTROPIC ACTIVITY DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1992-11-04 EP disclosed
US-5084456-A Analgesics SCIENCE ET ORGANISATION (FR) 1992-01-28 US disclosed
US-5079249-A Serotine antagonists at 5-HT2 level, antiallergens, antihistamines ADIR ET COMPAGNIE (FR) 1992-01-07 US disclosed
US-5071847-A BIS (ARYL) ALKENE COMPOUNDS OF HOMOPIPERIDINES USEFUL AS SEROTONIN-ANTAGONISTS ADIR ET COMPAGNIE (FR) 1991-12-10 US disclosed
US-5028607-A Antiserotonine agents ADIR ET COMPAGNIE (FR) 1991-07-02 US disclosed
US-4950670-A Psychological and cardiovascular disorders SYNTHELABO (FR) 1990-08-21 US disclosed
EP-0189612-A1 New pharmaceutical compositions having a psychotropic activity DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1986-08-06 EP disclosed
US-3857944-A 1-PIPERAZINOISOQUINOLINES AS INOTROPIC AGENTS SANDOZ AG 1974-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 HTR2C 4659/4885HRH4 4471/4885NCF1 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.